Explore

Trendline Trendline
Immunome to Present Phase 3 RINGSIDE Trial Data at ASCO Annual Meeting

Immunome to Present Phase 3 RINGSIDE Trial Data at ASCO Annual Meeting

Immunome to Present Phase 3 RINGSIDE Trial Data at ASCO Annual Meeting
Trendline Trendline
Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO
Trendline Trendline
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions
Trendline Trendline
Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026
Trendline Trendline
Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026

Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026

Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026
Trendline Trendline
IDEAYA Biosciences to Present Phase 2/3 Data on Darovasertib at ASCO 2026

IDEAYA Biosciences to Present Phase 2/3 Data on Darovasertib at ASCO 2026

IDEAYA Biosciences to Present Phase 2/3 Data on Darovasertib at ASCO 2026
Trendline Trendline
Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step

Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step

Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Trendline Trendline
Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer
Trendline Trendline
Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence
Trendline Trendline
Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value
Trendline Trendline
FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer